Gainers
- Medpace Hldgs MEDP shares moved upwards by 10.73% to $208.6 during Monday's after-market session. The market value of their outstanding shares is at $7.4 billion. As per the news, the Q3 earnings report came out today.
- HealthEquity HQY stock rose 4.99% to $71.27. HealthEquity's trading volume hit 65.1K shares by close, accounting for 13.36% of its average volume over the last 100 days. The market value of their outstanding shares is at $5.9 billion.
- Innate Pharma IPHA stock moved upwards by 4.54% to $5.52. The market value of their outstanding shares is at $437.6 million.
- Scopus BioPharma SCPS shares increased by 3.97% to $3.92. The market value of their outstanding shares is at $70.9 million.
- Eloxx Pharmaceuticals ELOX stock rose 3.67% to $1.41. The market value of their outstanding shares is at $121.5 million.
- Artelo Biosciences ARTL shares rose 3.65% to $0.73. The market value of their outstanding shares is at $17.9 million.
Losers
- Progenity PROG shares decreased by 4.44% to $3.23 during Monday's after-market session. Today's trading volume for this security ended up closing at 819.8K shares, which is 1.73 percent of its average volume over the last 100 days. The company's market cap stands at $428.7 million.
- Biotricity BTCY shares declined by 4.43% to $4.1. The company's market cap stands at $194.9 million.
- Simulations Plus SLP shares declined by 3.78% to $40.0. The company's market cap stands at $805.3 million. The company's, Q4 earnings came out today.
- Kiromic BioPharma KRBP stock fell 3.05% to $2.23. The company's market cap stands at $34.4 million.
- Minerva Neurosciences NERV stock declined by 3.04% to $1.28. The market value of their outstanding shares is at $54.6 million.
- Tonix Pharmaceuticals TNXP shares decreased by 2.09% to $0.55. This security traded at a volume of 151.5K shares come close, making up 1.18% of its average volume over the last 100 days. The market value of their outstanding shares is at $196.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in